IP Library Granted Patent US 8,088,371
Granted Patent B2
US 8,088,371 · App. 12/140,586 · Granted Jan 3, 2012

Compositions and minimally invasive methods for treating peripheral vascular disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,088,371
App. No.
12/140,586
Granted
Jan 3, 2012
Kind
B2
Abstract

Methods are described for using compositions containing platelet-rich plasma for the treatment of peripheral vascular disease. A platelet-rich plasma composition is introduced into the muscle or soft tissue in the area of hypovascularity to treat the peripheral vascular disease.

Claims (13)

1. A method for treating peripheral vascular occlusive disease in an individual comprising:

withdrawing whole blood from the individual;

preparing platelet rich plasma from the whole blood;

buffering the platelet rich plasma to a pH of about 7.3 to 7.5; and

delivering the platelet rich plasma to an area of hypovascularity in the individual thereby treating the peripheral vascular occlusive disease,

wherein an exogenous activator is not added to the platelet rich plasma nor is an exogenous activator administered to the area of hypovascularity.

2. The method of claim 1 , wherein the platelet rich plasma is delivered to a lower extremity in the individual.

3. The method of claim 1 , wherein the platelet rich plasma is delivered into and around the area of hypovascularity.

4. The method of claim 3 , wherein the platelet-rich plasma is introduced into the muscle or soft tissue.

5. The method of claim 1 , wherein delivering the platelet rich plasma comprises delivering the platelet rich plasma using a syringe.

6. The method of claim 1 , wherein delivering the platelet rich plasma comprises delivering three to five cubic centimeters of the platelet rich plasma.

7. The method of claim 1 , wherein buffering the platelet rich plasma comprises buffering with a buffer selected from the group consisting of sodium bicarbonate, calcium gluconate, choline chloride, EGTA, HEPES, maleic acid, MOPS, PIPES, TES, TRIS BASE, TRIS-HC1, and urea.

8. The method of claim 1 , wherein delivering the platelet rich plasma comprises injecting the platelet rich plasma.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2021
From: MISHRA, ALLAN, DR.
To: BLUE ENGINE BIOLOGICS, LLC
Reel/Frame 056759/0943 →